271 related articles for article (PubMed ID: 16105142)
1. Successful treatment with adalimumab in infliximab-resistant Crohn's disease.
Barthel HR; Gille T; Halbsguth A; Kramer M
J Gastroenterol Hepatol; 2005 Sep; 20(9):1464-5. PubMed ID: 16105142
[No Abstract] [Full Text] [Related]
2. Treatment of vulval Crohn's disease with infliximab.
Preston PW; Hudson N; Lewis FM
Clin Exp Dermatol; 2006 May; 31(3):378-80. PubMed ID: 16681581
[TBL] [Abstract][Full Text] [Related]
3. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease.
Sorrentino D; Terrosu G; Avellini C; Maiero S
Arch Intern Med; 2007 Sep; 167(16):1804-7. PubMed ID: 17846401
[No Abstract] [Full Text] [Related]
4. Methotrexate: the best choice for second-line maintenance treatment in active Crohn's disease?
Grimaldi C
Gastroenterol Clin Biol; 2009 Jan; 33(1 Pt 1):21-2. PubMed ID: 18977624
[No Abstract] [Full Text] [Related]
5. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab.
Laharie D; Reffet A; Belleannée G; Chabrun E; Subtil C; Razaire S; Capdepont M; de Lédinghen V
Aliment Pharmacol Ther; 2011 Mar; 33(6):714-21. PubMed ID: 21235604
[TBL] [Abstract][Full Text] [Related]
6. [Biological therapy as treatment of inflammatory bowel diseases].
Agnholt J
Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
[TBL] [Abstract][Full Text] [Related]
7. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].
Sansó Sureda A; Rocamora Durán V; Sapiña Camaró A; Royo Escosa V; Bosque López MJ
Gastroenterol Hepatol; 2011 Oct; 34(8):546-50. PubMed ID: 21665330
[TBL] [Abstract][Full Text] [Related]
8. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
Heidemann J; Kucharzik T
Z Gastroenterol; 2005 Jul; 43(7):689-90. PubMed ID: 16001352
[No Abstract] [Full Text] [Related]
9. [Adalimumab vasculitis in a patient with Crohn's disease].
Muñoz Villafranca C; Izu Belloso RM; Bravo Rodriguez MT; Basterra Olabarrieta S
Gastroenterol Hepatol; 2013 Apr; 36(4):296-7. PubMed ID: 23522950
[No Abstract] [Full Text] [Related]
10. Infliximab therapy in a patient with refractory ileocolic Crohn's disease and Takayasu arteritis.
Calderón R; Estrada S; Ramírez de la Piscina P; Salvador M; Zabaleta S; Enciso C; Delgado E; García-Campos F
Rev Esp Enferm Dig; 2010 Feb; 102(2):145-6. PubMed ID: 20361852
[No Abstract] [Full Text] [Related]
11. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial.
Savarino E; Bodini G; Dulbecco P; Assandri L; Bruzzone L; Mazza F; Frigo AC; Fazio V; Marabotto E; Savarino V
Am J Gastroenterol; 2013 Nov; 108(11):1731-42. PubMed ID: 24019080
[TBL] [Abstract][Full Text] [Related]
12. [Which place for methotrexate in treatment of luminal Crohn's disease?].
Carbonnel F
Gastroenterol Clin Biol; 2009 Jan; 33(1 Pt 1):18-20. PubMed ID: 19084362
[No Abstract] [Full Text] [Related]
13. Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab.
Cravo M; Silva R; Serrano M
BioDrugs; 2010 Dec; 24 Suppl 1():25-7. PubMed ID: 21175232
[TBL] [Abstract][Full Text] [Related]
14. Infliximab treatment induces levels of the active azathioprine metabolite TGTP in Crohn's disease.
Teichgräber U; Atreya I; Atreya R; Schwab M; Neurath MF
Inflamm Bowel Dis; 2013; 19(4):E54-5. PubMed ID: 22532373
[No Abstract] [Full Text] [Related]
15. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
Colombel JF; Loftus EV; Tremaine WJ; Pemberton JH; Wolff BG; Young-Fadok T; Harmsen WS; Schleck CD; Sandborn WJ
Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial.
Hinojosa J; Gomollón F; García S; Bastida G; Cabriada JL; Saro C; Ceballos D; Peñate M; Gassull MA;
Aliment Pharmacol Ther; 2007 Feb; 25(4):409-18. PubMed ID: 17269996
[TBL] [Abstract][Full Text] [Related]
17. Longstanding Crohn's vulvitis successfully treated with combined anti-TNFα antibody and azathioprine.
Macdonagh E; Pugh S; Fox R
J Obstet Gynaecol; 2013 Jul; 33(5):530. PubMed ID: 23815219
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
[TBL] [Abstract][Full Text] [Related]
19. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease.
Peyrin-Biroulet L; Oussalah A; Williet N; Pillot C; Bresler L; Bigard MA
Gut; 2011 Jul; 60(7):930-6. PubMed ID: 21228429
[TBL] [Abstract][Full Text] [Related]
20. [Cytomegalovirus primary infection in a patient with Crohn's disease treated with azathioprine and anti-TNF alpha].
Ben Hriz F; Habbessi H; Maamouri N; Belkahla N; Ouerdiane S; Chouaib S; Ouerghi H; Chaabouni H; Ben Mami N
Tunis Med; 2009 Aug; 87(8):545-6. PubMed ID: 20180364
[No Abstract] [Full Text] [Related]
[Next] [New Search]
